tradingkey.logo

Penumbra Inc

PEN
查看详细走势图
316.050USD
+0.700+0.22%
收盘 12/19, 16:00美东报价延迟15分钟
12.37B总市值
74.75市盈率 TTM

Penumbra Inc

316.050
+0.700+0.22%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.22%

5天

+1.29%

1月

+12.96%

6月

+23.04%

今年开始到现在

+33.08%

1年

+30.31%

查看详细走势图

TradingKey Penumbra Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Penumbra Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名19/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价313.05。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Penumbra Inc评分

相关信息

行业排名
19 / 208
全市场排名
82 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 20 位分析师
买入
评级
313.053
目标均价
+6.18%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Penumbra Inc亮点

亮点风险
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
业绩高增长
公司营业收入稳步增长,连续3年增长41.02%
估值低估
公司最新PE估值74.72,处于3年历史低位
机构减仓
最新机构持股37.12M股,环比减少7.80%
肯·费雪持仓
明星投资者肯·费雪持仓,最新持仓市值5.95K

Penumbra Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Penumbra Inc简介

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
公司代码PEN
公司Penumbra Inc
CEOElsesser (Adam)
网址https://www.penumbrainc.com/

常见问题

Penumbra Inc(PEN)的当前股价是多少?

Penumbra Inc(PEN)的当前股价是 316.050。

Penumbra Inc的股票代码是什么?

Penumbra Inc的股票代码是PEN。

Penumbra Inc股票的52周最高点是多少?

Penumbra Inc股票的52周最高点是320.000。

Penumbra Inc股票的52周最低点是多少?

Penumbra Inc股票的52周最低点是221.260。

Penumbra Inc的市值是多少?

Penumbra Inc的市值是12.37B。

Penumbra Inc的净利润是多少?

Penumbra Inc的净利润为14.01M。

现在Penumbra Inc(PEN)的股票是买入、持有还是卖出?

根据分析师评级,Penumbra Inc(PEN)的总体评级为买入,目标价格为313.053。

Penumbra Inc(PEN)股票的每股收益(EPS TTM)是多少

Penumbra Inc(PEN)股票的每股收益(EPS TTM)是4.228。
KeyAI